Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation
Dermatology · 2024
DOI: 10.1159/000534575 ↗Kurz gefasst
Leitlinie in der Zeitschrift Dermatology, 2024. Verfasst von Emily K Kozera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Liverpool Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Current infectious disease screening recommendations for hidradenitis suppurativa (HS) are adopted from recommendations in chronic plaque psoriasis. No HS-specific guidelines for infectious disease screening prior to immunomodulatory therapy have been developed.
Objectives
The aim of the study was to establish an expert Delphi consensus of recommendations regarding infectious disease screening prior to systemic immunomodulatory therapy in HS.
Methods
Participants were identified via recent publications in the field and were sent a questionnaire regarding infectious diseases encountered in the setting of HS, and opinions regarding infectious disease screening prior to various systemic immunomodulatory therapies. All questions were informed by a systematic literature review regarding infections exacerbated or precipitated by immunomodulatory therapy. Questionnaire responses were followed by round-table discussion with a core group of 8 experts followed by a final round of questionnaires resulting in achievement of consensus.
Results
44 expert HS physicians from 12 countries on 5 continents participated in the development of the expert consensus recommendations. Consensus recommendations include screening for hepatitis B, hepatitis C and tuberculosis in all individuals with HS prior to therapy. All immunomodulatory therapies (biologic and systemic immunosuppressant therapy) should be preceded by infectious disease screening including patient and location-specific considerations for endemic local diseases and high-risk activities and occupations. Clinical assessment has a significant role in determining the need for laboratory screening in the setting of many uncommon or tropical diseases such as leprosy, leishmaniasis and strongyloidiasis.
Conclusions
The presented consensus recommendations are the first specifically developed for pre-treatment infectious disease screening in HS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Liverpool Hospital, Sydney, New South Wales, Australia.
- Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Division of Dermatology, Baylor Scott and White, Dallas, Texas, USA.
- College of Medicine, Texas A and M University, Dallas, Texas, USA.
- Department of Dermatology, Mater Dei Hospital, Msida, Malta.
- Dermatology Department, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Zitieren
APA
Kozera, E. K., Porter, M., Paek, S. Y., Mintoff, D., McMeniman, E., Oon, H. H., Chandran, N. S., Glasenhardt, K., Ring, H. C., & Frew, J. W. (2024). Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation. Dermatology. https://doi.org/10.1159/000534575
Vancouver
Kozera EK, Porter M, Paek SY, Mintoff D, McMeniman E, Oon HH, et al. Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation. Dermatology. 2024. doi:10.1159/000534575
BibTeX
@article{Kozera2024,
author = {Kozera, Emily K and Porter, Martina and Paek, So Yeon and Mintoff, Dillon and McMeniman, Erin and Oon, Hazel H and Chandran, Nisha Suyien and Glasenhardt, Katalin and Ring, Hans Christian and Frew, John W},
title = {Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation},
journal = {Dermatology},
year = {2024},
doi = {10.1159/000534575}
}
EUVIMED